Circulation. 2023 Feb 14;147(7):e76-e91. doi: 10.1161/CIR.0000000000001124. Epub 2023 Feb 13.
This scientific statement summarizes the available preclinical, epidemiological, and clinical trial evidence that supports the contributions of prepregnancy (and interpregnancy) cardiovascular health to risk of adverse pregnancy outcomes and cardiovascular disease in birthing individuals and offspring. Unfavorable cardiovascular health, as originally defined by the American Heart Association in 2010 and revised in 2022, is prevalent in reproductive-aged individuals. Significant disparities exist in ideal cardiovascular health by race and ethnicity, socioeconomic status, and geography. Because the biological processes leading to adverse pregnancy outcomes begin before conception, interventions focused only during pregnancy may have limited impact on both the pregnant individual and offspring. Therefore, focused attention on the prepregnancy period as a critical life period for optimization of cardiovascular health is needed. This scientific statement applies a life course and intergenerational framework to measure, modify, and monitor prepregnancy cardiovascular health. All clinicians who interact with pregnancy-capable individuals can emphasize optimization of cardiovascular health beginning early in childhood. Clinical trials are needed to investigate prepregnancy interventions to comprehensively target cardiovascular health. Beyond individual-level interventions, community-level interventions must include and engage key stakeholders (eg, community leaders, birthing individuals, families) and target a broad range of antecedent psychosocial and social determinants. In addition, policy-level changes are needed to dismantle structural racism and to improve equitable and high-quality health care delivery because many reproductive-aged individuals have inadequate, fragmented health care before and after pregnancy and between pregnancies (interpregnancy). Leveraging these opportunities to target cardiovascular health has the potential to improve health across the life course and for subsequent generations.
本科学声明总结了现有临床前、流行病学和临床试验证据,这些证据支持妊娠前(和妊娠间)心血管健康对不良妊娠结局和分娩个体及后代心血管疾病风险的影响。正如美国心脏协会在 2010 年首次定义并在 2022 年修订的那样,不良心血管健康在育龄人群中普遍存在。理想心血管健康在种族和民族、社会经济地位和地理位置方面存在显著差异。由于导致不良妊娠结局的生物学过程始于受孕前,因此仅在怀孕期间进行干预可能对孕妇和后代的影响有限。因此,需要将重点放在妊娠前阶段,将其作为优化心血管健康的关键生命阶段。本科学声明应用生命历程和代际框架来衡量、调整和监测妊娠前心血管健康。所有与有生育能力的个体互动的临床医生都可以从儿童早期开始强调优化心血管健康。需要开展临床试验来研究妊娠前干预措施,以全面针对心血管健康。除了个体层面的干预措施外,社区层面的干预措施必须包括并吸引主要利益相关者(如社区领导、分娩个体、家庭),并针对广泛的先前心理社会和社会决定因素。此外,需要进行政策层面的改革,以消除结构性种族主义,并改善公平和高质量的医疗保健服务提供,因为许多育龄个体在妊娠前后和妊娠期间的医疗保健不足且碎片化(妊娠间)。利用这些机会针对心血管健康进行干预,有可能改善整个生命历程和后代的健康状况。